Company outlines path to leadership in BPH, including near-term focus on procedure growth through patient-centric solutions and increased organizational disciplineStrong revenue outlook, procedure growth, expanding margins, and path to profitabilityLonger-term growth drivers include market expansion and expanded application into prostate cancer NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient ...

SAN JOSE, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended December 31, 2025. “In the fourth quarter, we delivered our highest procedure volume to date—approximately 12,200—and sold 65 new systems, marking our strongest capital quarter,” said Larry Wood, Chief Executive Offic ...

Core Insights - PROCEPT BioRobotics is focused on advancing patient care in urology through transformative robotic solutions [3] - The company will present at two investor conferences in March 2026, indicating active engagement with the investment community [1][2] Company Overview - PROCEPT BioRobotics aims to revolutionize the treatment of Benign Prostatic Hyperplasia (BPH) globally by partnering with urologists [3] - The company manufactures the AQUABEAM® and HYDROS® Robotic Systems, with the HYDROS system being the only AI-powered technology delivering Aquablation therapy [3] - Aquablation therapy is designed to provide effective, safe, and durable outcomes for men suffering from lower urinary tract symptoms (LUTS) due to BPH, regardless of prostate size, shape, or surgeon experience [3] - BPH affects approximately 40 million men in the United States, highlighting a significant market opportunity for the company [3] Upcoming Events - The company will participate in the TD Cowen 46th Annual Health Care Conference and the 2026 Leerink Global Health Care Conference [2] - A live webcast of each event will be available on the company's website, with recordings archived for at least 90 days [2] - Specific event details include a fireside chat on March 2 at 11:40 am ET in Boston, MA, and another on March 10 at 8 am ET in Miami, FL [4]

Group 1 - The company, PROCEPT BioRobotics Corporation, will report its financial results for Q4 2025 on February 24, 2026, after market close, followed by a conference call at 4:30 p.m. Eastern Time [1] - An in-person investor day event is scheduled for February 25, 2026, at NASDAQ Headquarters in New York City, starting at 8:00 a.m. Eastern Time, with advance registration recommended [2] - Live webcasts of both the financial results and investor day will be available on the company's website, with recordings archived for at least 90 days [3] Group 2 - PROCEPT BioRobotics aims to revolutionize BPH treatment globally by providing advanced robotic solutions that enhance patient outcomes and deliver value [4] - The company manufactures the AQUABEAM® and HYDROS® Robotic Systems, with the HYDROS system being the only AI-powered technology for Aquablation therapy, designed for effective treatment of lower urinary tract symptoms in men [4] - BPH is the most common prostate disease, affecting approximately 40 million men in the United States [4]

Core Insights - PROCEPT BioRobotics Corporation reported a strong performance with a 43% year-over-year global revenue growth for Q3 2025, driven by increased demand for the HYDROS® Robotic System and Aquablation therapy adoption [3][4]. Financial Performance - Total revenue for Q3 2025 was $83.3 million, a 43% increase compared to Q3 2024 [4][9]. - U.S. revenue reached $73.9 million, reflecting a 42% growth year-over-year, primarily from system sales and increased handpiece revenue [4][9]. - U.S. handpiece and consumable revenue was $44.4 million, up 50% from the previous year, while system revenue was $24.7 million, a 26% increase [4][9]. - International revenue for the quarter was $9.4 million, marking a 53% increase compared to the prior year [4][9]. Gross Margin and Operating Expenses - Gross margin improved to 65% in Q3 2025 from 63% in the prior year, attributed to operational efficiencies despite increased tariff expenses [5]. - Operating expenses rose to $77.2 million from $59.3 million in the prior year, driven by expansion of the commercial organization and increased R&D and administrative expenses [6]. Net Loss and Adjusted EBITDA - The net loss for Q3 2025 was $21.4 million, slightly higher than the $21.0 million loss in Q3 2024 [7]. - Adjusted EBITDA loss improved to $7.4 million from a loss of $12.4 million in the prior year [7][18]. Cash Position - As of September 30, 2025, the company had cash, cash equivalents, and restricted cash totaling $297.3 million [7]. Full Year Guidance - The company maintains its revenue guidance for the full year 2025 at approximately $325.5 million, representing a 45% growth over the previous year [8][9]. - For 2026, the projected revenue is between $410 million and $430 million, indicating a growth of 26% to 32% compared to 2025 [10][9].